The third primary endpoint of time to cardiovascular death or first heart failure hospitalization in patients with transferrin saturation <20% occurred in 22 women in the treatment group compared with 15 in the placebo group (HR 1.21; 95% CI 0.62–2.36, p = 0.58). The gene discussed is TF; the disease is heart failure.